Journal of Internal Medicine Concepts & Practice >
Comparison of the efficacy of different budesonide inhalation devices in newly diagnosed mild bronchial asthma
Received date: 2025-10-31
Revised date: 2025-12-08
Accepted date: 2025-12-18
Online published: 2026-08-19
Copyright
Objective To compare the effects of regular inhaled corticosteroids (ICS) using different inhalation devices combined with on-demand short-acting β2-receptor agonist (SABA) on symptoms, respiratory impedance, lung function and airway inflammation in newly diagnosed patients with mild bronchial asthma. Methods A total of 53 patients with newly diagnosed mild bronchial asthma were prospectively enrolled. Using SAS software (version 9.4), the participants were randomly assigned in a 1:1 ratio to a pressurized metered-dose inhaler (pMDI) group of 26 patients and a dry powder inhaler (DPI) group of 27 patients. Both groups received budesonide 200 μg per dose twice daily for 4 weeks. Asthma control test (ACT) scores, lung function, impulse oscillometry (IOS) parameters, fractional exhaled nitric oxide (FeNO) and blood eosinophil (EOS) levels were assessed before and after treatment. Results There were no significant differences in baseline data, lung function, IOS, FeNO or EOS between the 2 groups (P>0.05). IOS parameters were correlated with lung function indicators. After 4 weeks of treatment, ACT scores increased, while FeNO and EOS decreased, and peak expiratory flow (PEF) increased compared with baseline in both groups (all P<0.05). The improvement in forced expiratory flow at 25% of forced vital capacity (FEF25%) in the pMDI group was significantly greater than that in the DPI group (P<0.05). Stratified analysis showed that in patients with small airway dysfunction (SAD), FeNO≥25 ppb, or EOS≥150 cells/μL, the pMDI group exhibited more significant FEF25% improvement after treatment (P<0.05). The proportion of patients achieving an ACT score of 25 in the pMDI group was significantly higher than that in the DPI group. Conclusions After 4 weeks of budesonide treatment in patients with newly diagnosed mild asthma, the change in FEF25% and the proportion with well-controlled symptoms were higher in the pMDI group than in the DPI group, while both are comparable in terms of airway inflammation improvement and safety. Baseline FEV1 reversibility and abnormalities in small airway function may predict a better therapeutic effect of pMDI.
ZHENG Qi , BAO Wuping , WANG Ning , SONG Yajun , ZHANG Min , ZHOU Yan . Comparison of the efficacy of different budesonide inhalation devices in newly diagnosed mild bronchial asthma[J]. Journal of Internal Medicine Concepts & Practice, 2026 , 21(03) : 222 -231 . DOI: 10.16138/j.1673-6087.2026.03.04
| [1] | 中华医学会呼吸病学分会. 支气管哮喘防治指南（2024年版）[J]. 中华结核和呼吸杂志, 2025, 48(3): 208-248. |
| Chinese Thoracic Society of Chinese Medical Association. Guidelines for the prevention and management of bronchial asthma (2024 edition)[J]. Chin J Tuberc Respir Dis, 2025, 48(3): 208-248. | |
| [2] | GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390(10100): 1211-1259. |
| [3] | Global Initiative for Asthma. Global strategy for asthma management and prevention （2024 update） [EB/OL]. [2024-05-22]. https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. |
| Global Initiative for Asthma. Global strategy for asthma management and prevention (2024 update) [EB/OL]. [2024-05-22]. https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. | |
| [4] | Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study[J]. Lancet, 2019, 394(10196): 407-418. |
| [5] | Shang B, Li X, Xu Y, et al. Clinical characteristics and economic burden of asthma in China: a multicenter retrospective study[J]. Iran J Allergy Asthma Immunol, 2023, 22(3): 290-298. |
| [6] | 中华医学会呼吸病学分会. 轻度支气管哮喘诊断与治疗中国专家共识（2023）[J]. 中华结核和呼吸杂志, 2023, 46(9): 880-896. |
| Chinese Thoracic Society of Chinese Medical Association. Expert consensus on the diagnosis, treatment and management of mild bronchial asthma in China (2023 edition)[J]. Chin J Tuberc Respir Dis, 2023, 46(9): 880-896. | |
| [7] | Usmani OS, Han MK, Kaminsky DA, et al. Seven pillars of small airways disease in asthma and COPD: supporting opportunities for novel therapies[J]. Chest, 2021, 160(1): 114-134. |
| [8] | King GG, Bates J, Berger KI, et al. Technical standards for respiratory oscillometry[J]. Eur Respir J, 2020, 55(2): 1900753. |
| [9] | Pisi R, Aiello M, Frizzelli A, et al. Detection of small airway dysfunction in asthmatic patients by spirometry and impulse oscillometry system[J]. Respiration, 2023, 102(7): 487-494. |
| [10] | Su ZQ, Guan WJ, Li SY, et al. Significances of spirometry and impulse oscillometry for detecting small airway disorders assessed with endobronchial optical coherence tomography in COPD[J]. Int J Chron Obstruct Pulmon Dis, 2018, 13: 3031-3044. |
| [11] | Srichana T, Juthong S, Thawithong E, et al. Clinical equivalence of budesonide dry powder inhaler and pressurized metered dose inhaler[J]. Clin Respir J, 2016, 10(1): 74-82. |
| [12] | Muraki M, Gose K, Hanada S, et al. Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?[J]. Drug Deliv, 2017, 24(1): 1395-1400. |
| [13] | 中国医学装备协会呼吸病学专委会吸入治疗与呼吸康复学组. 稳定期慢性气道疾病吸入装置规范应用中国专家共识（2023版）[J]. 中华结核和呼吸杂志, 2023, 46(11): 1055-1067. |
| Inhalation Therapy and Respiratory Rehabilitation Group of Respiratory Equipment Committee of China Association of Medical Equipment. Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)[J]. Chin J Tuberc Respir Dis, 2023, 46(11): 1055-1067. | |
| [14] | 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南（2020年版）[J]. 中华结核和呼吸杂志, 2020, 43(12): 1023-1048. |
| Asthma group of Chinese Throacic Society of Chinese Medical Association. Guidelines for bronchial asthma prevent and management (2020 edition)[J]. Chin J Tuberc Respir Dis, 2020, 43(12): 1023-1048. | |
| [15] | Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update[J]. An official American Thoracic Society and European Respiratory Society technical statement[J]. Am J Respir Crit Care Med, 2019, 200(8): e70-e88. |
| [16] | 中国医师协会呼吸医师分会肺功能与临床呼吸生理工作委员会, 中华医学会呼吸病学分会肺功能学组, 中国老年医学会呼吸分会肺功能学组. 肺功能检查技术规范——脉冲振荡技术检查[J]. 中华结核和呼吸杂志, 2022, 45(10): 960-969. |
| Pulmonary Function and Clinical Respiratory Physiology Committee of Chinese Association of Chest Physicians, Task Force for Pulmonary Function of Chinese Thoracic Society of Chinese Medical Association, Pulmonary Function Group of Respiratory Branch of Chinese Geriatric Society. Technical standards for pulmonary function tests: impulse oscillometry[J]. Chin J Tuberc Respir Dis, 2022, 45(10): 960-969. | |
| [17] | American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005[J]. Am J Respir Crit Care Med, 2005, 171(8): 912-930. |
| [18] | 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 常规肺功能检查基层指南（2018年）[J]. 中华全科医师杂志, 2019, 18(6): 511-518. |
| Chinse Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice of Chinese Medical Association, et al. Guideline for pulmonary function testing in primary care (2018)[J]. Chin J Gen Pract, 2019, 18(6): 511-518. | |
| [19] | Pisi R, Tzani P, Aiello M, et al. Small airway dysfunction by impulse oscillometry in asthmatic patients with normal forced expiratory volume in the 1st second values[J]. Allergy Asthma Proc, 2013, 34(1): e14-e20. |
| [20] | Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications[J]. Am J Respir Crit Care Med, 2011, 184(5): 602-615. |
| [21] | 周妍, 张旻. 我国轻度支气管哮喘诊治现状及对策[J]. 诊断学理论与实践, 2023, 22(6): 520-526. |
| Zhou Y, Zhang M. Current status and countermeasures of diagnosis and treatment of mild bronchial asthma in China[J]. J Diagn Concepts Pract, 2023, 22(6): 520-526. | |
| [22] | Chow MYT, Pan HW, Lam JKW. Delivery technology of inhaled therapy for asthma and COPD[J]. Adv Pharmacol, 2023, 98: 273-311. |
| [23] | Singh D, Roche N, Wu L, et al. In silico lung deposition profiles of three single-inhaler triple therapies in patients with COPD using functional respiratory imaging[J]. Int J Chron Obstruct Pulmon Dis, 2025, 20: 2103-2116. |
| [24] | Al-Ahmad M, Webb D. A prospective study of switching asthma patients from a fixed-dose combination (FDC) inhaled corticosteroid /long-acting beta agonist therapy delivered by dry powder inhaler (DPI) to ICS/LABA delivered by pressurised metered dose inhaler (pMDI)[J]. Respir Med, 2022, 194: 106771. |
| [25] | Woo SD, Ye YM, Lee Y, et al. Efficacy and safety of a pressurized metered-dose inhaler in older asthmatics: comparison to a dry powder inhaler in a 12-week randomized trial[J]. Allergy Asthma Immunol Res, 2020, 12(3): 454-466. |
| [26] | Kupczyk M, Majak P, Kuna P, et al. A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - a randomized, multi-center, non-inferiority, phase Ⅳ clinical study[J]. Respir Med, 2021, 176: 106274. |
| [27] | Ahookhosh K, Yaqoubi S, Mohammadpourfard M, et al. Experimental investigation of aerosol deposition through a realistic respiratory airway replica: an evaluation for MDI and DPI performance[J]. Int J Pharm, 2019, 566: 157-172. |
| [28] | Longest PW, Tian G, Walenga RL, et al. Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways[J]. Pharm Res, 2012, 29(6): 1670-1688. |
| [29] | 徐孜翀, 张旻, 赵磊, 等. 超细或细颗粒吸入糖皮质激素联合福莫特罗对支气管哮喘患者大小气道功能改善作用研究[J]. 中国医师进修杂志, 2023, 46(7): 587-594. |
| Xu ZC, Zhang M, Zhao L, et al. Effects of extrafine-particle versus fine-particle inhaled corticosteroids combined with formoterol on large and small airway function in patients with bronchial asthma[J]. Chin J Postgrad Med, 2023, 46(7): 587-594. | |
| [30] | Calzetta L, Aiello M, Frizzelli A, et al. Small airways in asthma: from bench-to-bedside[J]. Minerva Med, 2022, 113(1): 79-93. |
| [31] | 谢建芳, 朱琳, 刘莎, 等. 超细颗粒丙酸倍氯米松对哮喘患者小气道异常疗效的Meta分析[J]. 儿科药学杂志, 2023, 29(9): 19-25. |
| Xie JF, Zhu L, Liu S, et al. Meta-analysis of ultrafine beclomethasone dipropionate granules in the treatment of small airway abnormalities in children with asthma[J]. Journal of Pediatric Pharmacy, 2023, 29(9): 19-25. | |
| [32] | Soma T, Iemura H, Naito E, et al. Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma[J]. Allergol Int, 2018, 67S: S3-S11. |
| [33] | Afriyie-Mensah JS, Domoyeri P, Antwi-Boasiako C, et al. Relationship between fraction of exhaled nitric oxide and peripheral eosinophilia in asthma[J]. Ann Med, 2024, 56(1): 2382377. |
| [34] | 钱雪娇, 蒋萍. 2型炎症型哮喘发病机制[J]. 中华临床免疫和变态反应杂志, 2022, 16(6): 629-635. |
| Qian XJ, Jiang P. Pathogenesis of type Ⅱ inflammation subtype of asthma[J]. Chin J Allergy Clin Immunol, 2022, 16(6): 629-635. | |
| [35] | Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma phenotype[J]. Lancet Respir Med, 2014, 2(6): 497-506. |
| [36] | Papapostolou N, Makris M. Allergic asthma in the era of personalized medicine[J]. J Pers Med, 2022, 12(7): 1162. |
| [37] | 贺瑞珍. 脉冲震荡法测定哮喘患者小气道功能的临床研究[D]. 太原: 山西医科大学, 2019. |
| He RZ. A clinical study on the measurement of small airway function in asthmatic patients by impulse oscillometry system[D]. Taiyuan:Shanxi Medical University, 2019. | |
| [38] | Mas Fazlin MJ, Ching ZH, Azat AA, et al. Correlation between impulse oscillometry with bronchodilator reversibility in asthmatic population in a tertiary referral centre[J]. Med J Malaysia, 2024, 79(1): 21-27. |
| [39] | Huang S, Wu F, Deng Z, et al. Comparing spirometry, impulse oscillometry with computed tomography for assessing small airway dysfunction in subjects with and without chronic obstructive pulmonary disease[J]. BMC Pulm Med, 2025, 25(1): 45. |
| [40] | Hao H, Bao W, Xue Y, et al. Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV1 ≥ 80% predicted[J]. J Allergy Clin Immunol Pract, 2021, 9(8): 3098-3108. |
| [41] | Hao H, Pan Y, Xu Z, et al. Prediction of bronchodilation test in adults with chronic cough suspected of cough variant asthma[J]. Front Med, 2022, 9: 987887. |
| [42] | Zhang X, Xu Z, Lin J, et al. Sex differences of small airway function and fractional exhaled nitric oxide in patients with mild asthma[J]. Ann Allergy Asthma Immunol, 2023, 130(2): 187-198. |
| [43] | Bernstein DI, Hébert J, Cheema A, et al. Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma[J]. Allergy Asthma Clin Immunol, 2011, 7(1): 21. |
/
| 〈 |
|
〉 |
